Date Added: 27/06/2017
Date Updated: 27/06/2017
A transdermal glucagon patch for severe hypoglycemia
Specialties: Endocrine, nutritional and metabolic
Technology Type: Devices - Drugs
Stage of development: Experimental - pilot or phase II
Stage of EAA: Assessment Complete
The ZP-Glucagon patch uses novel microneedle technology to deliver glucagon through the skin to people who are experiencing severe hypoglycemia (very low blood sugar).
There is very limited evidence, from one small study, comparing the ZP-Glucagon patch with glucagon injected intramuscularly.
The evidence suggests that the correction of blood sugar levels is comparable between the ZP-Glucagon patch and the glucagon injected intramuscularly when tested in a controlled setting.
The ZP-Glucagon patch is not yet commercially available and the anticipated cost is unknown.
In an emergency situation, the ZP-Glucagon patch may be a more user-friendly option than injecting glucagon.
Keywords: Diabetes mellitus, Type 1 diabetes, glucagon, transdermal drug delivery, hypoglycemia